While the 'Pre Launch' and 'Go to Market Strategies' for Remestemcel-L sound great, they will be useless if the FDA issues yet another CRL
Upon further consideration, I anticipate any partnership deal will not be able to be finalised until the court officially signs off on the CA in September when the next hearing is scheduled in the Federal Court - makes sense in case it all goes pear shaped or the parasitic lawyers want more once they see the deal parameters because it wont be small
in my opinion.
SI seems very 'careful' or perhaps even 'restricted' in the wording used today re: FDA and the BLA ... nothing like what was
supposedly said to the Australian Newspaper ?
Question time should be interesting - can't imagine anyone of the brokers growing a pair and asking about the CA or mentioning the $26.5 million
(20min delay)